APA

Coles A. J., Fox E., Vladic A., Gazda S. K., Brinar V., Selmaj K. W., Bass A. D., Wynn D. R., Margolin D. H., Lake S. L., Moran S., Palmer J., Smith M. S. & Compston D. A. S. (20110615). Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. : The Lancet. Neurology.

Chicago

Coles Alasdair J, Fox Edward, Vladic Anton, Gazda Suzanne K, Brinar Vesna, Selmaj Krzysztof W, Bass Ann Doan-Do, Wynn Daniel R, Margolin David H, Lake Stephen L, Moran Susan, Palmer Jeffrey, Smith M Shelton and Compston D Alastair S. 20110615. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. : The Lancet. Neurology.

Harvard

Coles A. J., Fox E., Vladic A., Gazda S. K., Brinar V., Selmaj K. W., Bass A. D., Wynn D. R., Margolin D. H., Lake S. L., Moran S., Palmer J., Smith M. S. and Compston D. A. S. (20110615). Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. : The Lancet. Neurology.

MLA

Coles Alasdair J, Fox Edward, Vladic Anton, Gazda Suzanne K, Brinar Vesna, Selmaj Krzysztof W, Bass Ann Doan-Do, Wynn Daniel R, Margolin David H, Lake Stephen L, Moran Susan, Palmer Jeffrey, Smith M Shelton and Compston D Alastair S. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. : The Lancet. Neurology. 20110615.